

# ROBIN OligoMET Center

## Monthly Research Update: August 2022

### Publications

<b>AUGUST AT A GLANCE TOTALS</b>	
<b>Publications</b>	6
<b>Grants and contracts</b>	
New awards	2
Submitted	0
<b>Oral Presentations</b>	2
<b>Abstracts</b>	0
<b>Clinical trials</b>	
TERPS	0
<b>Awards/Honors</b>	2

Please submit all monthly updates to Jadyne Stewart at [jadynstewart@som.umaryland.edu](mailto:jadynstewart@som.umaryland.edu) by second Wednesday of each month.

1. Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, **Mishra M, Rana Z**, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, **Bentzen SM**, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, **Tran PT**. [Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials](#). J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. PMID: 36001857.
2. Kamran M, Bhattacharya U, Omar M, **Marchionni L**, Ince TA. [ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin](#). NPJ Breast Cancer. 2022 Aug 29;8(1):99. doi: 10.1038/s41523-022-00474-2. PMID: 36038558; PMCID: PMC9424319.
3. **Marchionni L**, Lobo FP, Kostadinov R, Serra A, Besso FG, Deaglio S, Stratta P, Berrino M, Zanettini C, Imada EL, Omar MN, Gaidano G, Bruno B, Saglio G, Amoroso A. [Donor-derived acute myeloid leukemia in solid organ transplantation](#). Am J Transplant. 2022 Aug 18. doi: 10.1111/ajt.17174. Epub ahead of print. PMID: 35979657.
4. Wang S, Ryan Russell J, Drescher M, Park A, Legesse T, Kundra V, **Tran PT**, Phelan M, Naslund M, Minhaj Siddiqui M. [Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy](#). Prostate. 2022 Dec;82(16):1520-1528. doi: 10.1002/pros.24425. Epub 2022 Aug 3. PMID: 35923127.
5. Velu P, Cong L, Rand S, Qiu Y, Zhang Z, Zhang J, Guo J, Ruggiero P, Sukhu A, Fauntleroy K, **Imada E**, Zanettini C, Brundage D, Westblade L, **Marchionni L**, Cushing MM, Rennert H. [Rapid detection of SARS-CoV-2 variants of concern by single nucleotide polymorphism genotyping using TaqMan assays](#). Diagn Microbiol Infect Dis. 2022 Aug 21;104(4):115789. doi: 10.1016/j.diagmicrobio.2022.115789. Epub ahead of print. PMID: 36122486; PMCID: PMC9392658.
6. Wang S, Ryan Russell J, Drescher M, Park A, Legesse T, Kundra V, **Tran PT**, Phelan M, Naslund M, Minhaj Siddiqui M. [Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy](#). Prostate. 2022 Dec;82(16):1520-1528. doi: 10.1002/pros.24425. Epub 2022 Aug 3. PMID: 35923127.

### Grants and Contracts

#### Funded:

- **Lei Ren, PhD, PI**, from NIH/NIBIB, for “eXtended Modular ANthropomorphic (XMAN) phantom for Imaging and Treatment Optimization in Radiotherapy,” R01EB032680, (Sept 2022- May 2026; \$2,569,436)
- **Phuoc T. Tran, MD, PhD**, PI/PD lead, other multi-PI/PDs **Amit Sawant, PhD**, and **Nicole Simone, MD** (Thomas Jefferson, University), from the National Cancer Institute (U54 CA273956) for “Radiation Oncology–Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center” (August 2022–July 2027; \$7,525,939).

**ROBIN OligoMET Center**  
**Monthly Research Update: August 2022**

## Grants and Contracts (continued)

**Submitted:**

- None at this time

## Oral Presentations

- **Lei R.** Duke-Kunshan University Summer School Lecture (August, 2022 – Kunshan, Jiangsu, China) “Advances and Applications of AI in IGRT”
- **Phuoc T.** NIH Moonshot NCI Drug Resistance and Sensitivity Network (DRSN) Annual Meeting (August 8, 2022 – Portland, OR). “Tumor-barcoding coupled with high-throughput sequencing of a novel chemoradiation resistant SCLC mouse model”.

## Abstracts

- None at this time

## Clinical Trial Enrollment

- 0 patients were enrolled (0/122) on the **TERPS trial**.

## Awards/Honors

- **Mark M.** was named the Radiation Therapy Oncology Group (RTOG) Foundation Research Committee Co-Chair
- **Nicole S.** has been invited to serve as Councilor-at-Large at the Radiation Research Society.

*Please note that these examples are representative of productivity from the ROBIN OligoMET Center members and are not exclusively attributable to the U54 grant.*